Vaxneuvance Market Report 2026

Vaxneuvance Market Overview

• The Vaxneuvance market growth in the historic period has been driven by expansion of routine pneumococcal vaccination programs, rising incidence of pneumococcal infections • Market expansion is supported by increasing investments in next-generation vaccines, rising focus on elderly immunization • Growth Driver: Impact Of High Pneumonia Prevalence On Vaccine Demand • Market Trend: Advanced Pneumococcal Vaccine Offers Broader Protection Across Age Groups • North America was the largest region in 2025.

What Is Covered Under Vaxneuvance Market?

Vaxneuvance is a pneumococcal conjugate vaccine designed to protect against invasive diseases caused by specific strains of Streptococcus pneumoniae in adults and children. The vaccine works by stimulating the immune system to recognize and fight 15 serotypes of the bacteria, providing broad protection. The main indication for vaxneuvance is pneumonia, meningitis, sepsis, bacteremia, and otitis media. Pneumonia is an infection that inflames the air sacs in the lungs, causing symptoms such as cough, fever, and difficulty breathing. Vaxneuvance helps prevent pneumococcal pneumonia by targeting specific serotypes of the streptococcus pneumoniae bacteria. The various distribution channels include pharmacies and hospitals, and several end users including adults, children, and geriatric population.

What Is The Vaxneuvance Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in next-generation vaccines, rising focus on elderly immunization, expansion of national immunization programs, growing demand for higher-valency vaccines, increasing adoption in emerging healthcare systems. Major trends in the forecast period include increasing adoption of broad-spectrum pneumococcal vaccines, rising focus on invasive disease prevention, growing pediatric and adult immunization coverage, expansion of conjugate vaccine technologies, enhanced emphasis on high-risk population protection.

What Are The Drivers Of The Vaxneuvance Market?

The prevalence of pneumonia is expected to drive the growth of the vaxneuvance market going forward. Pneumonia is an infection that causes inflammation in the air sacs of one or both lungs, filling with fluid or pus, resulting in symptoms such as coughing, fever, and breathing difficulties. The prevalence of pneumonia is driven by factors such as viral and bacterial infections, weakened immune systems, air pollution, and the increasing aging population, which makes individuals more susceptible to respiratory infections. Vaxneuvance helps patients by protecting against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infections and related complications. For instance, in 2024, according to the Johns Hopkins University, a US-based research university, the mean Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was 56%, an increase of 2% from 54% in 2023. Therefore, the high prevalence of pneumonia is driving the growth of the vaxneuvance industry. The growth in research and development investments is expected to drive the vaxneuvance market going forward. Investments in research and development are growing due to increasing demand for innovation and the need to address complex global challenges such as healthcare, sustainability, and digital transformation. The growing investments in research and development support Vaxneuvance by enhancing its vaccine technology and expanding its potential to address evolving healthcare needs. For instance, in April 2025, according to The Office for National Statistics (ONS), a UK-based producer of official statistics, the UK government’s net R&D spend increased by 8.2% year-on-year, rising from $19.9 billion in 2022 to $21.5 billion in 2023. Therefore, the growth in investments in research and development is driving the growth of the vaxneuvance industry.

Key Players In The Global Vaxneuvance Market

Major companies operating in the vaxneuvance market are Merck & Co. Inc.

Global Vaxneuvance Market Trends and Insights

Major companies operating in the vaxneuvance (pneumococcal conjugate vaccine) market are focusing on developing innovative solutions, such as next‑generation multivalent conjugate vaccines, to provide broader protection against pneumococcal infections. Next-generation multivalent conjugate vaccines are advanced vaccines designed to protect against multiple strains of a pathogen by linking polysaccharides from each strain to a carrier protein, enhancing immune response. For instance, in May 2025, Vietnam Vaccine JSC (VNVC), a US-based company, introduced the pneumococcal 15-valent conjugate vaccine (PCV15 or Vaxneuvance) to expand protection against multiple strains of Streptococcus pneumoniae responsible for invasive and non-invasive diseases. The vaccine targets children from six weeks of age as well as adults, offering long-lasting immunity and helping reduce the transmission of pneumococcal bacteria within the community. This launch positions VNVC at the forefront of modern pneumococcal vaccination in Vietnam, complementing its existing portfolio of pneumococcal vaccines and strengthening national immunization efforts.

What Defines the Vaxneuvance Market?

The vaxneuvance market consists of sales of pneumococcal 15-valent conjugate vaccines, adjuvants, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vaxneuvance Market Report 2026?

The vaxneuvance market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vaxneuvance industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.